It was a pleasure to talk to Pat Penovich (Minnesota Epilepsy Group, St. Paul, MN, USA) about the exit survey, of a Phase 3 study, assessing patient experience of using the diazepam nasal spray for seizure clusters. The abstract ‘Examining the Patient Experience With Diazepam Nasal Spray for Seizure Clusters: Patient-reported Results From an Exit Survey of a Phase 3, Open-label, Repeat Dose Safety Study.’ was presented at the virtual AES 2020, 4-8 December 2020.
- What are the advantages of intranasal delivery of rescue medications compared with current options in patients with epilepsy clusters? (0:05)
- Could you tell us a little about the diazepam nasal spray and it’s indications? (1:36)
- Could you give us an overview of your recent study on patient experience with diazepam nasal spray? (2:44)
- What were the findings of the study and what are the implications for future clinical practice? (3:50)
- Which patients are most likely to benefit from the diazepam nasal spray? (5:12)
Disclosures: Consultant and on Speaker’s Bureau for Neurelis, SK and UCB; Speaker’s Bureau for Greenwich; and Consultant for Marinus and LVIS.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of AES 2020, 4-8 December, 2020 (Virtual).
Share this Video
Related Videos In Epilepsy
Pat Penovich, AES 2020 – The Patient Experience With Diazepam Nasal Spray
It was a pleasure to talk to Pat Penovich (Minnesota Epilepsy Group, St. Paul, MN, USA) about the exit survey, of a Phase 3 study, assessing patient experience of using the diazepam nasal spray for seizure clusters. The abstract ‘Examining the Patient Experience With Diazepam Nasal Spray for Seizure Clusters: Patient-reported Results From an Exit […]
Martin Brodie, CONy 2020 – Combination Antiepileptic Drug Therapy
It was a pleasure to speak with Martin Brodie (President, International Bureau for Epilepsy and co-Section Head of Epilepsy for CONy), who spoke with us on the topic of the debate session he participated in: Should combination antiepileptic drug (AED) therapy be offered immediately after failure of a single antiepileptic drug? Questions Could you tell […]
Ingrid Scheffer, AES 2020 – Long Term Efficacy and Safety of Fenfluramine in Patients with Dravet Syndrome
We were delighted to talk to Ingrid Scheffer (The University of Melbourne, The Royal Children’s Hospital and Austin Health, Victoria, Australia) regarding the open-label extension study of fenfluramine in patients with Dravet syndrome (Clinical Trial Identifier: NCT02823145). The abstract ‘Efficacy and Tolerability of Adjunctive FINTEPLA (Fenfluramine Hydrochloride) in an Open-Label Extension Study of Dravet Syndrome […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!